Pharmaceuticals firm Syngene International declares Q4FY22 result: Syngene reports full year revenue from operations up 19% to Rs. 2604 Cr The Company reported revenue from operations up 15% to Rs. 758 Cr for the fourth quarter and up 19% to Rs. 2604 Cr for the full year ending 31 March 2022. Profit After Tax for the quarter, before accounting for exceptional items, was up 7% year-on-year to Rs. 148 Cr. Profit After Tax for the full year was up 10% to Rs. 421 Cr. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “I am pleased with the strong finish we had to the year and that we delivered results at the high end of our upgraded guidance range. Reflecting on the pandemic period, we created more than 1000 new jobs in the last two years and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc. and continued to invest in new capacity and technology to underpin future growth. Looking ahead, we see growing demand for research, development and manufacturing services around the world and we are well-positioned to take advantage of these new opportunities.” Result PDF
Conference Call with Syngene International Ltd. Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. Management in attendance: CEO Johnathan Hunt
Pharmaceuticals company Syngene International declares Q3FY22 result: Syngene reports 10% growth in revenue from operations to Rs. 6,414 Mn and raises full-year guidance The Company reported revenue from operations growth of 10% year-on-year to Rs. 6,414 Mn, delivering 10% growth in profit before tax to Rs. 1,284 Mn. Profit after tax for the quarter was Rs.1,040 Mn, representing year-on-year growth of 2%. Growth in profit after tax was impacted by a lower effective tax rate in the third quarter last year due to a tax reversal and other factors. For the nine months to December 31 2021, the Company delivered growth of 21% in revenue from operations to Rs.18,461 Mn and profit after tax, before exceptional items, was Rs 2,733 Mn, an increase of 12% compared the same period in the previous year. Based on the Company’s performance to date and the anticipated project deliveries in the fourth quarter, the Company updated the full year revenue growth guidance to high teens, from the mid-teen guidance shared at the beginning of the financial year. Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “Syngene’s performance across all divisions has been positive through the year, and we expect a busy fourth quarter. As a result, we have raised our revenue growth guidance for the full year to high teens. A highlight for the quarter was the extension of our long-standing collaboration with Amgen Inc until 2026. Since 2012, Syngene has been partnering with Amgen on research and development to address some of the most serious diseases in the world. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new stateof-the-art dedicated laboratory to accelerate the advancement of Amgen’s R&D; projects. The 5-year renewal of the long-standing contract with Amgen, coming on the heels of the 10- year contract extension signed with BMS last year, confirms the stability of both relationships and provides a clear perspective on the future of our Dedicated Centers.” Result PDF